Staar Surgical (NSDQ:STAA) announced today that it won CE Mark approval for use of its three ICL lenses as supplemental lenses in post-cataract intraocular lenses surgery patients (pseudophakics). Lake Forest, Calif.-based Staar Surgical’s Evo, Evo+ and Visian lenses all earned the European approval. The Evo/Evo+ and Visian devices are implantable collamer lenses designed to treat myopia […]
LumiThera closes second Series C financing round
LumiThera announced today that it closed the second tranche of its Series C financing round with more than $10 million raised. The photobiomodulation (PBM) treatment developer earmarked the proceeds from the funding round for further clinical testing and commercialization of its Valeda light delivery system for treating dry age-related macular degeneration (AMD). LumiThera’s Valeda system […]
J&J Vision launches Tecnis Toric II intraocular lens in U.S.
Johnson & Johnson (NYSE:JNJ) Vision announced that, after winning FDA approval, it launched the Tecnis Toric II one-piece intraocular lens (IOL) to treat astigmatism in cataract patients. The Tecnis Toric II IOL is Johnson & Johnson Vision’s first approved product within the Tecnis Toric II platform, which offers more surface texture and friction on IOL haptics, […]
Precision Optics announces offering of 760,000 shares
Precision Optics (OTCQB:PEYE) has stockholders selling 760,000 shares of its common stock, but the company is not selling any securities itself in the offering. PEYE stock was trading at $1.50 per share before Precision Optics listed the offering. The company’s shares are currently listed at $1.48 per share in mid-afternoon trading today. Because Precision Optics […]
Glaukos completes Avedro buy
Glaukos (NYSE:GKOS) today said it completed its acquisition of Glaukos for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. Get the full story on our sister site, Drug Delivery Business.
CooperVision wins FDA approval for myopia contact lens for kids
CooperVision (NYSE:COO) said that it won FDA approval for its MiSight one-day contact lens for slowing the progression of myopia when initially prescribed for children between 8-12 years old. The San Ramon, Calif.–based company announced the clearance for the first and only FDA-approved product clinically proven to slow myopia (nearsightedness or short-sightedness) yesterday. CooperVision said […]
FDA approves CooperVision’s contact lens to slow nearsightedness in kids
The FDA has approved the first contact lens indicated to slow the progression of nearsightedness in children between the ages of 8 and 12 years old. The MiSight contact by CooperCompanies’ (NYSE:COO) CooperVision lens is a single-use, disposable, soft contact lens that is discarded at the end of each day and is not intended to be worn […]
Ocular Therapeutix dips on Q3 losses
Ocular Therapeutix (NSDQ:OCUL) shares fell today on third-quarter results that narrowly topped the consensus forecast despite a bottom-line dip. The Bedford, Mass.–based ophthalmic insert maker posted losses of -$18,778, or -45¢ per share, on sales of $829,000 for the three months ended Sept. 30, for a 25.1% bottom-line slide on sales growth of 66.5%. Adjusted to […]
Glaukos slides on Q3 profit drop
Glaukos (NYSE:GKOS) shares dropped today on third-quarter earnings that topped the consensus forecast despite sliding profits. The San Clemente, Calif.-based ophthalmic medical technology and pharmaceutical company posted losses of -$13.5 million, or -37¢ per share, on sales of $58.5 million for the three months ended Sept. 30, for a large bottom-line slide on sales growth of […]
Regenxbio pulls trigger on option to license Clearside Biomedical’s SCS Microinjector
Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions. The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on […]
Clearside Biomedical inks $76m licensing deal with Bausch for Xipere
Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Get the full […]
- 1
- 2
- 3
- …
- 72
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube